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Summary
Background: Receptor tyrosine phosphatases (RPTPs)
are essential for axon guidance and synaptogenesis in
Drosophila. Each guidance decision made by embry-
onic motor axons during outgrowth to their muscle tar-
gets requires a specific subset of the five neural RPTPs.
The logic underlying these requirements, however, is
still unclear, partially because the ligands recognized
by RPTPs at growth cone choice points have not been
identified. RPTPs in general are still “orphan receptors”
because, while they have been found to interact in vitro
with many different proteins, their in vivo ligands are
unknown.
Results: Here we use a new type of deficiency screen
to identify the transmembrane heparan sulfate proteo-
glycan Syndecan (Sdc) as a ligand for the neuronal
RPTP LAR. LAR interacts with the glycosaminoglycan
chains of Syndecan in vitro with nanomolar affinity. Ge-
netic interaction studies using Sdc and Lar LOF muta-
tions demonstrate that Sdc contributes to LAR’s func-
tion in motor axon guidance. We also show that
overexpression of Sdc on muscles generates the same
phenotype as overexpression of LAR in neurons and
that genetic removal of LAR suppresses the phenotype
produced by ectopic muscle Sdc. Finally, we show that
there is at least one additional, nonproteoglycan, ligand
for LAR encoded in the genome.
Conclusions: Taken together, our results demonstrate
that Sdc on muscles can interact with neuronal LAR in
vivo and that binding to Sdc increases LAR’s signaling
efficacy. Thus, Sdc is a ligand that can act in trans to
positively regulate signal transduction through LAR
within neuronal growth cones.
Introduction
Signaling through tyrosine phosphorylation is essential
for axon guidance. Two large families of enzymes, pro-
tein tyrosine kinases (PTKs) and protein tyrosine phos-
phatases (PTPs), directly control phosphorylation of ax-
onal proteins on tyrosine residues. Many of the PTPs
are receptor-like molecules (RPTPs) that have extracel-
lular domains related in sequence to cell-adhesion
molecules (CAMs), connected via a single transmem-
brane domain to either one or two cytoplasmic PTP do-
mains.
The structural similarity of RPTPs to receptor tyrosine
kinases (RTKs) has led to the hypothesis that extracel-
lular ligands modulate RPTP activity, as they do with*Correspondence: zinnk@caltech.eduRTKs. To date, however, RPTPs are still “orphan recep-
tors” because, while they have been found to interact
with many different proteins, their physiologically rele-
vant ligands are unknown (reviewed by [1]). The only
RPTP-ligand interaction that has been shown to have
an effect on signaling is that of RPTP-β/ζ with the
secreted growth factor pleiotrophin/HB-GAM; pleiotro-
phin binding increases phosphorylation of β-catenin in
cell culture [2]. RPTP-β/ζ binds to a number of other
proteins in vitro as well, including known CAMs (re-
viewed by [3]).
Several RPTPs can mediate homophilic adhesion,
suggesting that they function as their own ligands (re-
viewed by [1]). The mammalian LAR RPTP can bind to
a laminin-nidogen complex [4]. Finally, and most rele-
vant to the present study, in vitro binding studies have
shown that heparin and heparan sulfate proteoglycans
(HSPGs) directly interact with avian RPTPσ, a close rel-
ative of LAR. This same RPTP also binds to a non-
HSPG protein in muscle [5]. However, it is unknown
whether HSPGs or the muscle protein contribute to
RPTPσ function in vivo [6].
Drosophila has provided a unique system for investi-
gation of the in vivo roles of RPTPs during neural devel-
opment (reviewed by [7]). The fly genome encodes six
RPTPs, five of which are selectively expressed in neu-
rons. Genetic studies of these five neural RPTPs have
shown that they are required for axon guidance and
synaptogenesis during both embryonic and larval
stages.
Embryonic motor axons navigate to their muscle tar-
gets along five major nerve pathways (ISN, ISNb, ISNd,
SNa, and SNc; see http://www.its.caltech.edu/wzinnlab/
motoraxons/fma%20home%20page.html for diagrams
and images of the motor axon/muscle system). Analy-
sis of motor axon guidance phenotypes in Rptp single
mutants and mutant combinations has revealed that
each growth cone guidance decision made by motor
axons requires a specific subset of the five neural
RPTPs [8–13]. Most Rptp single mutant phenotypes are
partially penetrant, because several RPTPs can partici-
pate in each guidance decision. To generate a highly
penetrant alteration in motor axon guidance, it is usu-
ally necessary to remove a specific combination of two
or more RPTPs.
The combinatorial roles of RPTPs in regulating spe-
cific guidance decisions could be explained by a model
in which ligands for particular RPTPs are located near
each growth cone choice point and that these control
the specificity of RPTP function. In this model, a partic-
ular RPTP might participate in an axon guidance deci-
sion only if its ligand is contacted by the relevant
growth cones at the time at which they are making the
decision.
The RPTP LAR is involved in guidance of ISNb motor
axons at the entrance to their target ventrolateral mus-
cle (VLM) field. In Lar mutants, these axons leave the
common ISN pathway at the “exit junction” but then fail
to enter the VLM field to innervate their muscle targets.
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jacent to the common ISN pathway.
In this paper, we employ a deficiency screen to iden-
tify a cell-surface HSPG, Syndecan (known as Sdc in
Drosophila) [14], as an in vivo ligand for LAR. Synde-
cans are cell-surface HSPGs that have transmembrane
regions. However, they can also be cleaved to produce
free extracellular domains that are shed into the me-
dium. Another class of cell-surface HSPGs, the glypi-
cans, is attached to the membrane via glycosyl-phos-
phatidylinositol (GPI) linkages (reviewed by [15]).
Syndecans consist of an extracellular core protein
domain of w250 amino acids (aa) to which long glyco-
saminoglycan (HS-GAG) side chains are attached, fol-
lowed by a transmembrane domain and a short cyto-
plasmic domain. The GAG chains are composed of
repeating disaccharide units that are sulfated at spe-
cific positions. They are attached, polymerized, and
modified by a complex biosynthetic pathway involving
the activities of many different enzymes.
HSPGs are involved in many different cellular pro-
cesses, among which are adhesion, motility, prolifera-
tion, differentiation, and morphogen transport. In Dro-
sophila, the glypicans Dally and Dally-like (Dlp) are
required for Hedgehog and Wingless singnaling (re-
viewed by [15, 16]). Cell-surface HSPGs can function
as receptors for soluble ligands, as ligands for recep-
tors on adjacent cell surfaces, and as coreceptors for
other transmembrane signaling proteins on the same
cells. HSPGs shed into the medium can act as soluble
ligands for receptors on surrounding cells.
HSPGs also have roles in axon guidance. They work
together with FGF signaling to control axon guidance
in the Xenopus visual system and are required for
attraction of growth cones to Semaphorin 5A (reviewed
by [17, 18]). HSPGs also regulate axon guidance via the
Slit/Robo pathway in Drosophila and zebrafish [19–21].
Our findings in this paper provide a new mechanism
for HSPG-mediated axon guidance. We identified Sdc
in a screen for ligands of the Drosophila LAR RPTP and
characterized its interactions with LAR by using bio-
chemistry and genetics. Our results indicate that Sdc
expressed on muscles can positively regulate LAR sig-
naling in motor neurons.
Results
A Deficiency Screen for Genes Encoding
LAR Ligands
To search for ligands of the Drosophila RPTPs, we first
devised an in vivo staining procedure based on the
affinity probe techniques developed by Flanagan and
colleagues (reviewed by [22]). For LAR, the entire extra-
cellular domain of the protein (consisting of three im-
munoglobulin-like [Ig] domains and nine fibronectin
type III [FN] repeats) was fused to human placental al-
kaline phosphatase (PLAP), and the resulting fusion,
LAR-AP, was expressed as a secreted protein using the
baculovirus system.
To detect and localize putative LAR ligands, live-dis-
sected stage 16 embryonic filets were incubated with
LAR-AP in the absence of nonionic detergent, followed
by fixation and probe detection using secondary and
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erimental Procedures available with this article online).
ncubation of wild-type filets with LAR-AP reveals a
omplex staining pattern, including CNS axons (Figure
B), intense stripes of staining at muscle attachment
ites in the periphery (Figure 1C), and a segmentally
epeated pattern of midline and exit glia in the CNS
Figure 1A). The muscle attachment site and glial stain-
ng patterns have distinctive dot-like morphologies. We
lso generated and tested similar AP fusion proteins for
he DPTP10D, DPTP99A, and DPTP69D RPTPs, and we
ound that each produces a distinctive staining pattern
n live embryo filets (A. Schmid, A.N.F., and K.Z., un-
ublished results). Unconjugated PLAP and a variety of
ther AP fusion proteins exhibited no specific binding
o embryos (Figure S1, Table S1).
To identify the genomic region(s) encoding the puta-
ive LAR ligands responsible for this staining pattern,
e dissected and stained live embryos homozygous for
ach of the deletion mutations in the Bloomington
tock Center deficiency kit, which at that time con-
ained about 225 lines. We identified a second chromo-
ome deletion, Df(2R)AA21, which eliminated the bright
eripheral LAR-AP staining at muscle attachment sites
nd also removed most of the dot-like glial staining.
NS axons were still stained in deletion embryos,
owever.
By performing complementation crosses with over-
apping deletions and staining embryos from these
rosses with LAR-AP, we were able to narrow down the
egion required for staining to a small interval (57E1–9)
ust proximal to the Egfr gene. The interval contains
nly four identified genes: Sdc, Sara, Fkbp13, and
ESK2 (Figure 1J).
yndecan Is a Ligand for LAR
dc, a transmembrane HSPG, was the logical candi-
ate for the LAR ligand encoded in this region, because
t is the only predicted cell-surface protein. Further-
ore, an avian LAR ortholog had already been shown
o bind to HSPGs [6]. To test this hypothesis, we exam-
ned Sdc mutant embryos for LAR-AP staining. We
sed three different Sdc mutations. SdcDf(2R)48 is aw20
b deletion that removes N-terminal Sdc coding region
nd also deletes all or part of the Sara and Fkbp13
enes [20]. Sdc10608 and SdcKG06163 are independent P
lement insertion mutations in an Sdc intron (Figure 1J).
ll three of these mutations eliminated the dot-like
AR-AP staining of muscle attachment sites and glia
Figures 1D and 1E, Table S1). Mutations in Sara or
kbp13 had no effect on LAR-AP staining (Table S1).
Sdc mRNA and protein are expressed in a variety of
issues in the embryo [14, 20, 21]. Strikingly, Sdc pro-
ein is expressed at high levels in a dot-like pattern at
uscle attachment sites, and this pattern appears
dentical to that component of the peripheral LAR-AP
taining pattern that is eliminated by Sdc mutations
compare Figures 1C and 1G). Sdc is also expressed at
igh levels on CNS axons (Figure 1F), which stain with
AR-AP. However, staining of CNS axons by LAR-AP is
etained in zygotic Sdc mutants (Figure 1D), although
taining for Sdc is greatly reduced (Figures 1H and 1I),
ndicating that other putative LAR ligand(s) are also lo-
alized to axons (see below).
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1703Figure 1. LAR-AP Staining of Drosophila Em-
bryos Identifies Sdc as a LAR Binding
Protein
Each image shows four abdominal segments
of the CNS and the ventral muscle region in
a live-dissected stage 16 embryo filet; ante-
rior is up. Staining is visualized with immuno-
fluorescence (40× objective). The muscle at-
tachment sites shown are at the ends of the
longitudinal ventral (15, 16, 17) and ven-
trolateral (7, 6, 13, 12) muscles. Scale bar
equals 10 m.
(A–C) Three focal planes of LAR-AP staining
of a wild-type embryo filet.
(A) LAR-AP, dorsal (top) focal plane. Arrows
indicate midline glia.
(B) LAR-AP, middle focal plane. Arrow indi-
cates staining of CNS longitudinal tracts.
(C) LAR-AP, ventral (deep) focal plane. Ar-
rowhead indicates staining of ventral CNS
midline cells; arrow indicates muscle attach-
ment site staining. Note the characteristic
dot-like morphology of the muscle attach-
ment site staining.
(D and E) LAR-AP staining of an SdcKG06163
embryo filet.
(D) Middle focal plane, showing that staining
of the CNS axon ladder is still prominent (ar-
row). The axon ladder is somewhat dis-
torted; this is the Sdc phenotype.
(E) Ventral focal plane, showing that periph-
eral staining at muscle attachment sites is
greatly reduced (arrow). Arrowhead: ventral
CNS midline cells.
(F and G) Anti-Sdc staining of a wild-type
embryo filet.
(F) Dorsal focal plane, showing that Sdc is
expressed on CNS axons (arrow).
(G) Ventral focal plane, showing bright dot-
like anti-Sdc staining of muscle attachment
sites (arrow). Note that this pattern is essen-
tially identical to the LAR-AP attachment site
staining in (C).
(H) Anti-Sdc staining of an SdcDf48 (zygotic
null) embryo filet, using the same exposure
time as (F) and (G). Sdc protein levels are
much reduced.
(I) A much longer exposure of anti-Sdc staining of the same embryo filet, demonstrating that maternally contributed Sdc protein still localizes
to CNS axons (arrow).
(J) A map of the Sdc-Egfr region. Df(2R)AA21 lacks peripheral LAR-AP staining and anti-Sdc staining. Df(2R)C4 retains LAR-AP and anti-Sdc
staining. The mapped breakpoint of AA21 is to the left of the C4 breakpoint, but our results show that it must actually lie to its right, within
Sdc. Df(2R)Egfr5 deletes Egfr and extends to the left. The Sdc10608 and SdcKG06163 insertions are both located near the 5# end of the large
Sdc intron. SdcDf48 was generated by imprecise excision of Sdc10608.LAR-AP staining of muscle attachment sites can be
blocked by adding excess heparin, a highly sulfated
form of HS. This implies that LAR-AP interacts with Sdc
through its HS-GAG side chains, rather than with the
Sdc protein core. In keeping with this, LAR-AP binding
to the periphery is eliminated in embryos mutant for
sulfateless (sfl), sugarless (sgl), and tout-velu (ttv) (Fig-
ure S1, Table S1). These genes encode enzymes that
are necessary for GAG chain synthesis and sulfation,
and HSPG levels are reduced in zygotic mutant larvae
lacking each of these enzymes [23].
The Drosophila genome encodes two other cell-sur-
face HSPGs, the glypicans Dally and Dally-like (Dlp) [24,
25]. There is also a Perlecan, an extracellular matrix
HSPG, encoded by the trol gene [26, 27]. To examine
whether any of these proteins contribute to the LAR-AP staining pattern observed on wild-type embryos, we
stained dally single mutants, dally dlp double mutants,
and trol mutants. No changes from the normal staining
pattern were observed (Figure S1, Table S1).
To further demonstrate that LAR-AP interacts with
Sdc, we ectopically expressed Sdc in muscles and
showed that this ectopic muscle Sdc can be recog-
nized by LAR-AP. LAR-AP was also able to bind to the
glypican Dally when it was expressed at high levels on
muscles (Figure S2).
Evidence for a Second LAR Ligand
In Sdc mutants, while the bright dot-like LAR-AP stain-
ing at muscle attachment sites is absent, staining of
CNS axons is still prominent (Figure 1D). There are also
faint double lines extending into the periphery in each
Current Biology
1704hemisegment, which probably correspond to specific
muscle edges or attachment sites (Figure 2F, arrow-
heads). The residual staining in Sdc mutants is resistant
to heparin, suggesting that it is mediated by a non-
HSPG protein. This protein is not LAR itself, because
staining of CNS axons is unchanged in Lar null mutant
embryos (Table S1).
To characterize interactions with the putative second,
non-HSPG, LAR ligand(s), and to further prove that
LAR-AP interacts with Sdc through its GAG chains, we
expressed mutant versions of LAR-AP with point muta-
tions in putative HS binding motifs in the first Ig do-
main. Such mutants would be expected to be unable
to interact with Sdc but might bind normally to non-
HSPG ligands.
We made two mutants that we predicted would elimi-
nate HS binding based on sequence analysis and on
the RPTPσ mutants made by [6]. The canonical HS
binding motif is BBXBB (B = K or R) [28]. In LAR-HS1-
AP, we mutated the motif 61RKNGKK66 to 61AANGAA66.
In LAR-HS2-AP, the basic cluster 101RAGR104 was mu-
tated to 101AAGA104. AP fusion proteins were produced
for both mutants, and results reported below show that
these do not bind well to heparin or HSPGs.
Figures 2C and 2D show two focal planes of staining
of wild-type embryo filets with LAR-HS2-AP. This pro-
tein stains CNS axons and double lines in the periph-
e
t
t
m
a
i
f
t
b
L
o
S
S
o
w
t
o
a
L
W
R
s
w
f
t
eFigure 2. A Heparan Sulfate Binding-Defective LAR-AP Protein, LAR-HS2-AP, Stains CNS Axons and Peripheral Lines in Sdc Mutant Embryos
Images of stage 16 embryo filets like those in Figure 1. Scale bar equals 10 m.
(A) LAR-AP staining of wild-type embryo, middle focal plane, showing CNS axons (arrow).
(B) LAR-AP, same wild-type embryo as (A), ventral focal plane, showing muscle attachment site staining (arrowhead).
(C) LAR-HS2-AP, wild-type, middle focal plane, showing CNS axons (arrow).
(D) LAR-HS2-AP, same wild-type embryo as (C), ventral focal plane. Note the absence of bright dot-like staining in the periphery. This has
been replaced by faint double lines extending into the periphery in each segment (arrowheads).
(E) LAR-AP, Sdc maternal/zygotic mutant embryo, middle focal plane, showing CNS axons (arrow).
(F) LAR-AP, same Sdc mutant embryo as (E), ventral focal plane, showing faint double lines in the periphery (arrowheads). Note that this
pattern is almost identical to that in (D), indicating that the remaining LAR-AP staining in the absence of Sdc is the same as that seen with
an HS binding-defective mutant in wild-type.
(G) LAR-HS2-AP, Sdc maternal/zygotic mutant embryo, middle focal plane, showing CNS axons (arrow).
(H) LAR-HS2-AP, same Sdc mutant embryo as (G), ventral focal plane, showing faint double lines in the periphery (arrowheads). Note that this
pattern is also like that in (D), indicating that the HS binding-defective mutant binds in the same manner to wild-type embryos and to embryos
lacking Sdc.ry; the pattern in the periphery is quite distinct from
hat seen with LAR-AP (compare to Figure 2B). To prove
hat this staining pattern is independent of Sdc, we
ade maternal/zygotic Sdc mutant embryos that lack
ny detectable Sdc protein. This can be done by cross-
ng SdcDf48, ubi-Sara/Sdc10608 females (in which Sara
unction is rescued by a transgene, allowing survival)
o SdcDf48, ubi-Sara/CyO-GFP males. When these em-
ryos are stained with LAR-AP (Figures 2E and 2F) or
AR-HS2-AP (Figures 2G and 2H), an identical pattern
f staining is observed with the two fusion proteins.
imilar results were obtained with LAR-HS1-AP (Table
1). In summary, these findings indicate that at least
ne other cell-surface-associated protein can interact
ith the extracellular domain of LAR and that this in-
eraction is not mediated through HS GAGs. This sec-
nd LAR ligand (or ligands) is expressed on CNS axons
nd in a distinct pattern in the periphery.
AR Interacts with Sdc and Heparin In Vitro
e characterized interactions of LAR and the other
PTPs with HS in vitro using a solid-phase binding as-
ay with heparin-agarose beads. In this assay, beads
ere mixed with each AP fusion protein at the same
usion protein concentration (approximately 2 nM), so
hat the extent of binding reflects the relative affinity of
ach fusion protein for the beads. These results showed
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the HS1 and HS2 mutants discussed above. If we as-
sume that HS1 and HS2 binding reflects the level of
nonspecific interaction with the beads (the HS1 muta-
tion eliminates the only canonical HS binding motif in
LAR), this leads to the conclusion that DPTP69D and
DPTP99A do not bind specifically to heparin-agarose.
However, some binding of DPTP10D-AP over back-
ground is observed in this assay (Figure 3A).
We then performed similar experiments with two Dro-
sophila cell lines: Kc167, which makes Sdc at high
levels, and S2, which makes very little Sdc [14]. The
binding profile with Kc167 cells was similar to that seen
with heparin-agarose, except that the HS2 mutant ex-
hibited more binding than HS1 and DPTP10D-AP did not
bind (Figure 3B). For S2 cells, LAR-AP bound at 3-fold
lower levels than to Kc167 cells, while the other pro-
teins bound at levels similar to those seen with Kc167
cells. These data suggest that Kc cells bind to LAR-AP
through Sdc. Kc167 cells do express mRNAs for the
glypicans Dally and Dlp, so glypican binding could
contribute to LAR-AP’s interactions with Kc167 cells.
However, we found that treatment of Kc167 cells with
phosphatidylinositol-specific phospholipase C, which
releases glypicans from the cell surface by cleaving GPI
linkages, did not reduce binding of LAR-AP (data not
shown).
We then performed saturation binding experiments
with heparin-agarose beads, Kc167 cells, and FLAG-
tagged secreted Sdc made in human 293T cells. The
binding plots are shown in Figures 3C–3E. We calcu-
lated affinities from these plots using nonlinear regres-
sion fitting of the data to a single-site binding model.
This method has been shown to yield more accurate
calculated affinities than Scatchard analysis when the
two methods are compared side by side using theFigure 3. In Vitro Binding of LAR-AP to Hepa-
rin-Agarose Beads, Drosophila Cells, and
Recombinant Sdc
(A) Bar graph of binding of RPTP-AP fusion
proteins to heparin-agarose beads. Bound
protein/total protein (calculated from assays
of AP activity) is expressed as a percentage.
Fusion proteins are at an approximate con-
centration of 2 nM. LAR-AP binds well to
heparin-agarose beads, while much less
binding is observed with the HS1 and HS2
mutants and the other RPTP-APs.
(B) Bar graph of binding of RPTP-AP fusion
proteins to Drosophila S2 and Kc167 cells.
Conditions as in (A). w3-fold more LAR-AP
binding is observed with Kc167 cells than
with S2 cells, while the other AP proteins
bind similarly to S2 and Kc167 cells.
(C–E). Saturation binding curves. Heparin-
agarose beads (C), Kc167 cells (D), and su-
pernatant from Sdc-FLAG-expressing hu-
man 293T cells (E) were incubated with the
indicated concentrations of LAR-AP. The
mean and standard error of three measure-
ments of bound LAR-AP are plotted. Best fit
binding curves (solid lines) were calculated
by linear regression analysis to derive the in-
dicated Kds and extrapolated maximum
binding values.same primary data [29]. The calculated Kd value for
LAR-AP binding to heparin-agarose is 0.18 nM (Figure
3C). For Kc167 cells, it is 0.78 nM (Figure 3D). Finally,
analysis of binding of LAR-AP to secreted, FLAG-
tagged Drosophila Sdc from 293T cell supernatants
yielded a Kd of 0.44 nM (Figure 3E). The calculated Kd
values obtained from our experiments are very similar
to those determined by Aricescu et al. in their analysis
of HSPG binding to the avian LAR ortholog RPTPσ. The
Kd values derived from their experiments were 0.32 nM
(heparin), 0.18 nM (agrin), and 0.21 nM (collagen XVIII) [6].
We were also able to coimmunoprecipitate LAR-AP
and Sdc by mixing LAR-AP protein with supernatant
from Sdc-FLAG-transfected HEK 293T cells, precipitat-
ing the secreted Sdc with anti-FLAG, and detecting
LAR-AP by immunoblotting with anti-PLAP (Figure S3).
In summary, these results indicate that LAR binds se-
lectively to HS and to Sdc in vitro.
Sdc Contributes to LAR’s Motor
Axon Guidance Function
Lar mutants display a characteristic motor axon guid-
ance phenotype called ISNb bypass [8, 10]. ISNb axons
normally innervate the VLM field, including muscles 6,
7, 12, and 13. These axons initially fasciculate with the
common ISN pathway, exiting the CNS via the ISN root.
They then leave the ISN at the exit junction and grow
into the muscle field (Figures 4A, 4B, and 4D). In Lar
mutant embryos, ISNb axons successfully split away
from the ISN pathway at the exit junction, but then
some or all of these axons fail to grow into the muscle
field at their normal entry point. Instead, they travel
along parallel to the ISN, underneath the muscles, until
they reach the dorsal edge of the VLM field (Figures 4C,
4E, and 4F). Zygotic null Lar mutant embryos display
a complete or partial ISNb bypass phenotype with a
Current Biology
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(A–C) Schematic diagrams of ISNb axons and their muscle targets at late stage 16. The ISNb is blue, ISN is red, ISNd is dark green, and the
VLMs (numbered) are light green. Dorsal is at top.
(A) Normal ISNb pathway, side view (internal to left). The ISNb leaves the ISN at the exit junction (EJ) and turns inward to target the VLMs. It
is thus in a more superficial focal plane than the ISN when viewed from the internal side (as in a filet preparation).
(B) Top view, like that seen in a filet preparation. The ISNb has begun to form synapses on the VLMs (horizontal bars). The ISNd extends
along the axis of the ventral muscles.
(C) The bypass phenotype characteristic of Lar mutants, top view. The ISNb leaves the ISN but then fails to enter the muscle field and grows
along parallel to the ISN and in the same (external) plane. The ISNd does not extend.
(D–H) Each panel shows two abdominal hemisegments of a late stage 16 embryo filet stained with mAb 1D4 using HRP immunohistochemistry
and visualized with DIC optics (63× objective). Dorsal is at top and anterior to left. Muscles 6, 7, 12, and 13 are labeled in some panels. i,
ISN; d, ISNd; t, transverse nerve; a, SNa. Scale bars equal 5 m. Scale bar in (D) is also used for (E); scale bar in (F) is also used for (G) and (H).
(D) Hemisegments A5 and A6 of a wild-type embryo. The focal plane is at the level of the VLMs. Note that the ISNb is in the same focal plane
as the muscles, while the ISN is out of focus under the VLMs.
(E and F) Bypass phenotype, in hemisegments A5 and A6 of a Lar13.2/Lar5.5 embryo.
(E) The focal plane is at the level of the VLMs. Note that no axons are in focus, because the ISNb is now under the VLMs.
(F) The focal plane is at the level of the ISN, external to (under) the muscles. The ISNb and ISN are seen as two parallel bundles in both
hemisegments (arrows); the ISNb appears to rejoin the ISN near the dorsal edge of the VLMs.
(G and H) Bypass phenotype, in hemisegments A5 and A6 of a Lar13.2 Sdc10608/Lar5.5 SdcDf48 embryo.
(G) The focal plane is at the level of the VLMs. Note that the ISNb is out of focus, because it is under the VLMs. However, a “foldback” branch
of the ISNb (arrow) has grown back ventrally from the ISNb after it passed under the VLMs and is forming a synapse on muscle 13.
(H) The focal plane is at the level of the ISN, under the muscles. The ISNb and ISN are seen as two parallel bundles in the right hemisegment
(arrows); the ISNb appears to rejoin the ISN near the dorsal edge of the VLMs. The arrowhead indicates the point at which the foldback
axon(s) leave the ISNb to grow back over the VLMs.
(I) A bar graph showing the % of A2–A7 hemisegments that exhibit partial or complete ISNb bypass in various genotypes. The numbers of
hemisegments scored are as follows: Oregon R = 395; SdcDf48, ubi-Sara/SdcDf48 maternal/zygotic mutant (see text) = 240; Lar13.2/Lar5.5 =
332; Larbypass = 211; Larbypass SdcDf48 = 171; Larbypass, SdcKG06163 = 263; Larbypass, Sdc10608 = 163; Lar13.2 Sdc10608/Lar5.5 SdcDf48 = 273;
**p < 0.01.penetrance of 25%–30% (i.e., 25%–30% of A2-A7 ab-
dominal hemisegments in late stage 16 embryos have
ISNb axons that bypass the VLMs). This penetrance
can also be influenced by maternal genotype, suggest-
ing that some Lar function is provided maternally. When
mothers bearing Df(2L)E55, which removes N-terminal
Lar coding sequence and may act as a dominant nega-
tive, are crossed to males bearing a null Lar point muta-
tion, the penetrance of the bypass phenotype increases
to w70% [8, 10].
To determine whether Sdc’s interactions with LAR are
important for ISNb axon guidance, we studied genetic
interactions between Lar and Sdc. We first examined
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lmbryos homozygous for each of the three Sdc alleles
escribed above (zygotic Sdc mutants), as well as ma-
ernal/zygotic Sdc mutants, and we found that they dis-
lay ISNb bypass at frequencies only slightly greater
han in wild-type (Figure 4I, Figure S4A). We then com-
ined the three Sdc mutations with three different Lar
utations and evaluated whether the penetrance of the
SNb bypass phenotype in these double mutants was
ncreased above the levels observed in the correspond-
ng Lar single mutants.
We initially made double mutants with each of the
hree Sdc mutations together with the hypomorphic al-
ele Larbypass, for which the bypass phenotype occurs
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1707at a penetrance of about 10%. This mutation introduces
a frame shift that causes deletion of the second PTP
domain [30]. These double mutants had bypass pheno-
types indistinguishable from those in Lar mutants and
did not display any new motor axon guidance pheno-
types. For each of the Sdc alleles, the bypass pene-
trance in the double mutants is increased by more than
2-fold above that seen for Larbypass. The largest effect
is observed for Sdc10608, where penetrance increases
from 10% in Larbypass to 26% in Larbypass Sdc10608 (Fig-
ure 4I; p < 0.01).
We also combined SdcDf48 and Sdc10608 with Lar13.2
and Lar5.5, which are early stop codon (presumed null)
mutations, and evaluated bypass phenotypes in the re-
sultant double transheterozygote. These double mu-
tants displayed an increased penetrance of the bypass
phenotype (43%; Figures 4G–4I) relative to the corre-
sponding Lar transheterozygote (28%; p < 0.01). This
indicates that removal of Sdc reduces the residual LAR
function that is retained in zygotic Lar-null embryos.
We combined Sara and Fkbp13 mutations with
Larbypass in order to ensure that effects of Sdc muta-
tions on these genes were not responsible for the in-
crease in bypass frequency observed in Lar Sdc combi-
nations. To determine if the interactions between Lar
and Sdc were specific for this HSPG, or might be also
observed for the other cell-surface HSPGs, we also ex-
amined double and triple mutants in which Larbypass
was combined with Dally and Dlp mutations. In all of
these cases, no increase in the frequency of the bypass
phenotype over that seen in the Lar single mutant was
observed (Figure S4A).
Sdc Expressed on Muscles Can Function
as a Ligand for Neuronal LAR
LAR is an axonal protein enriched on growth cones [8,
31, 32] (Figure S5). ISNb axons begin to grow into the
VLM field at mid-stage 15 [10]. We visualized Sdc ex-
pression at that time in order to determine whether it
is appropriately localized to influence LAR-expressing
growth cones entering the muscle field. Figures 5A and
5B show that Sdc is transiently expressed on patchesFigure 5. Sdc Is Expressed on Cells Adjacent
to the Motor Nerves at the Appropriate Time
to Influence ISNb Guidance
Live-dissected embryo filets were stained
with anti-Sdc (red) and anti-HRP (green) to
visualize the motor nerves (40× objective).
Hemisegments A3–A5 are shown. Anterior is
up and ventral to left. Scale bar equals 5 m.
(A) Anti-Sdc staining alone, in a mid-stage 15
embryo. Arrows indicate patches of staining
between the motor nerves.
(B) Merge of anti-Sdc and anti-HRP staining
(same anti-Sdc image). The circle shows the
region of the exit junction/muscle field entry
site; arrowheads indicate growth cones in
this vicinity. Note that the Sdc patches are
immediately posterior to the motor nerves.
The bright green structure to the left of
images (B) and (C) is the edge of the CNS.
Asterisk indicates ISN.
(C) Sdc and anti-HRP, in an early stage 16
embryo. The broad patches of Sdc staining have become narrower and are farther from the motor nerves (arrows); these will converge to the
muscle attachment site staining seen in Figure 1. The ISNb has formed a distinct pathway within the VLM field by this time (arrowheads).of cells immediately adjacent to the growing ISNb
nerve, consistent with the hypothesis that trans interac-
tions between LAR and Sdc could regulate muscle
field entry.
The genetic interaction results in Figure 4 suggest
that Sdc is a positive regulator of LAR function, since
the penetrance of the bypass phenotype in Lar LOF
mutants increases when Sdc is removed. To obtain fur-
ther information about how Sdc regulates LAR, we
wished to devise a genetic test of whether Sdc can in-
crease LAR signaling when expressed in trans to LAR.
To do this, we first needed to define a gain-of-function
(GOF) Lar axon guidance phenotype and then deter-
mine if this same phenotype can be produced by over-
expressing Sdc on muscles. We could then perform an
epistasis test, determining whether genetic removal of
LAR function would be able to suppress the Sdc over-
expression phenotype. If so, this would suggest that
the axon guidance phenotype caused by Sdc overex-
pression arises through an increase in LAR’s signaling
activity mediated by interactions between muscle Sdc
and neuronal LAR.
We first examined motor axons in embryos in which
wild-type LAR was overexpressed in neurons, and we
found guidance phenotypes affecting the SNa nerve.
No ISNb phenotypes were observed. SNa axons leave
the CNS in the SN root, and the nerve bifurcates dorsal
to muscle 12 and splits into two branches that inner-
vate muscles 21–24 (anterior branch) and muscles 5
and 8 (posterior branch) (Figures 6A and 6B). LAR over-
expression from the elav-GAL4 driver produced SNa bi-
furcation phenotypes with a frequency of 23%. The an-
terior and posterior branches were equally likely to be
affected (Figures 6C and 6F). This is a specific Lar GOF
phenotype; Lar LOF mutants do not display SNa phe-
notypes ([11] and Figure S4A). However, Ptp52F LOF
mutants display this same SNa phenotype, with a sim-
ilar penetrance (28% for nulls). Interestingly, LAR and
PTP52F have opposing activities in regulation of CNS
axon guidance [12].
Generation of the Lar SNa GOF phenotype requires
enzymatic activity, because overexpression of a LAR
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(A) Schematic diagram of the SNa nerve and the surrounding muscles. SNa is shown in dark red, and the ISN is in pink. The SNa usually
bifurcates at the ventral end of the cleft between muscles 22 and 23; it innervates muscles 5, 8, and 21–24. i, ISN; b, ISNb. Scale bar equals
5 m.
(B–E) Each image shows one or two abdominal hemisegments of a late stage 16 embryo stained with mAb 1D4 using HRP immunohistochem-
istry and visualized with DIC optics (63× objective). Muscles are numbered in some panels.
(B) Hemisegments A4 and A5 of a wild-type embryo. Arrows indicate the SNa bifurcation points.
(C) Hemisegment A4 in an elav-GAL4 × UAS-LAR (LAR neuronal overexpression) embryo. The posterior branch of the SNa is missing. In (C)–
(E), the arrows indicate the approximate points at which the SNa would have bifurcated if both branches were present.
(D) Hemisegment A3 in a 24B-GAL4 × UAS-Sdc (Sdc muscle overexpression) embryo. The posterior branch is missing.
(E) Hemisegment A3 in an Sdc muscle OE embryo. The anterior branch is missing.
(F) A bar graph showing the % of A2–A7 hemisegments that exhibit loss of at least one SNa branch in various genotypes. The numbers of
hemisegments scored are as follows: UAS-Sdc-III/+ (isogenic control) = 206; UAS-Sdc-III/24B-GAL4 = 241; Lar5.5/Lar13.2;UAS-Sdc-III/24B-
GAL4 = 124; elav-GAL4/UAS-Lar-wild-type = 159; elav-GAL4/UAS-Lar-C/S = 215. ***p < 0.001.mutant with point mutations of the essential catalytic
cysteine residues in both PTP domains does not pro-
duce SNa phenotypes at a greater frequency than the
isogenic control (Figure 6F).
We then examined motor axon guidance in embryos
overexpressing Sdc in muscles using the 24B-GAL4
driver and found identical SNa bifurcation phenotypes
(Figures 6D–6F), with a penetrance of 18%; again, no
ISNb phenotypes were observed. These results show
that exposure of SNa motor axons to excess muscle
Sdc causes bifurcation failures. We could now perform
the key epistasis experiment, determining whether these
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ohenotypes are suppressed when LAR is genetically re-
oved from the motor axons. We introduced a Lar null
utant combination into lines in which Sdc is overex-
ressed in muscles. This completely suppressed the
Na bifurcation phenotype (to 7%, versus 6% for the
sogenic UAS-Sdc insertion line control; Figure 6F; p <
.001). These results indicate that Sdc on muscles can
unction in vivo as a ligand for LAR on motor axons and
uggests that interaction in trans with Sdc increases
AR’s signaling activity. Finally, to examine the specific-
ty of the Sdc GOF phenotype, we also tested muscle
verexpression of the glypicans Dally and Dlp using the
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170924B and G14 drivers. Dally overexpression produced
SNa bifurcation phenotypes at a low penetrance (12%),
while Dlp overexpression did not produce any pheno-
type (Figure S4B).
Discussion
In this paper, we identify the HSPG Sdc as a ligand for
the RPTP LAR, a neuronal transmembrane receptor
that regulates axon guidance in embryos and larvae.
LAR interacts with the GAG chains of Sdc and binds
to heparin and Sdc with nanomolar affinity (Figure 3).
Genetic interaction studies using Sdc and Lar LOF mu-
tations demonstrate that Sdc contributes to LAR’s
function in motor axon guidance (Figure 4). We also
show that overexpression of Sdc on muscles generates
the same phenotype as overexpression of LAR in neu-
rons and that genetic removal of LAR suppresses the
phenotype produced by ectopic Sdc (Figure 6). These
results demonstrate that Sdc can interact with LAR in
trans and suggest that Sdc is a positive regulator of
LAR signaling in growth cones.
Using Deficiency Screens to Identify Ligands
for Cell-Surface Receptors
We describe a new strategy for identification of ligand
genes. First, the extracellular domain of the cell-surface
receptor of interest is expressed as an AP fusion pro-
tein [33]. Second, the AP fusion protein is used to stain
live-dissected Drosophila embryos to reveal the ex-
pression pattern of the putative ligand. Third, embryos
homozygous for each of the deletion mutations in the
Bloomington deficiency kit (which currently covers
>92% of the genome) are dissected and stained with
the AP fusion protein. If a deletion is identified that
eliminates all or part of the staining pattern, overlap-
ping deficiencies and insertion mutations can then be
screened to isolate the gene responsible for the staining.
This type of screen has several advantages over ex-
pression cloning from cDNA library pools in transfected
mammalian cells. First, expression cloning requires full-
length cDNA clones and is thus difficult if the ligand
mRNA is rare and/or large. This is not a concern with
the deficiency screen, since one is searching for re-
gions whose deletion eliminates staining, not for clones
that confer staining. Second, if two or more subunits
must come together to create a binding-competent li-
gand, this ligand will not be expressed by cells trans-
fected with library pools, since any given pool would
be unlikely to contain cDNAs for both subunits. How-
ever, the absence of a gene encoding one of the sub-
units would still be detected by the deficiency screen.
Third, expression cloning is normally limited to cell-sur-
face ligands, because soluble ligands would diffuse
away from the transfected cell. The deficiency screen
can permit cloning of genes encoding soluble ligands,
as long as these remain attached to structures in the
embryo during incubation with the AP fusion protein.
There are, however, several problems with the defi-
ciency screen approach. First, about 1/4 of kit deficien-
cies cannot be screened because homozygous em-
bryos have such severe phenotypes that staining
patterns cannot be recognized. This is due to removalof genes (e.g., Egfr at 57E9; Table S1) whose zygotic
expression is necessary for early development. To ad-
dress this problem, we are examining smaller deletions
in these “unscreenable regions” in order to narrow
down the regions that cannot be screened to the small-
est possible intervals around critical genes such as
Egfr. Second, the deficiency screen does not necessar-
ily locate the actual ligand genes; it would also identify
regions encoding genes required for ligand synthesis.
For example, deletion of the ttv, sgl, or sfl genes, which
encode enzymes required for GAG synthesis, elimi-
nates or reduces peripheral staining with LAR-AP, since
these enzymes are necessary to make binding-compe-
tent Sdc. Finally, some receptors may recognize multi-
ple ligands that are expressed in the same or similar
patterns. In this case, a deletion removing the gene en-
coding one of these ligands might not perturb staining
sufficiently to allow it to be identified in a screen. This
is presumably the case for the second CNS ligand of
LAR-AP (Figures 1 and 2). Sdc is also expressed on
CNS axons; thus, a deficiency removing the CNS ligand
would probably not eliminate axonal LAR-AP staining
since Sdc would still be present in these embryos. To
deal with this problem, we are now rescreening the de-
ficiency kit with LAR-HS2-AP (Figures 2 and 3), a point
mutant that cannot interact with Sdc.
Regulation of Motor Axon Guidance by Sdc
Genetic removal of Sdc from embryos bearing Lar mu-
tations increases the penetrance of the characteristic
Lar ISNb bypass phenotype. This effect on penetrance
is as large as those usually observed when a second
RPTP is genetically removed from a single Rptp mutant
(e.g., removal of DPTP69D from a Lar mutant [10]).
Removal of Sdc increases penetrance for both hypo-
morphic and (zygotic) null Lar mutations (Figure 4). The
effect on the null penetrance is likely due to reduction
of maternally contributed LAR function [10]. However,
we found that Sdc mutations alone do not produce
ISNb bypass at a significant frequency, even when both
maternal and zygotic Sdc are removed (Figure 4, Figure
S4A). One explanation for this finding might be that Sdc
is partially redundant with Dally and/or Dlp, since these
are cell-surface HSPGs expressed in a similar pattern
to Sdc.
To test this model, we reduced Dally and Dlp expres-
sion in an Sdc mutant background. It is difficult to as-
sess the appropriate extent of reduction for this experi-
ment. Glypicans cannot be completely removed, since
this would produce embryos with severe early pheno-
types due to loss of Hedgehog and Wingless signaling
(reviewed by [15, 16]). We generated zygotic triple mu-
tants (Sdc dally dlp), and we also injected dally and
dlp dsRNAs into Sdc maternal/zygotic mutant embryos
(dally/dlp RNAi would affect both maternal and zygoti-
cally contributed mRNAs). The genetic triple mutants
had CNS phenotypes that are stronger than the Sdc
phenotype [20, 21] but displayed few motor axon guid-
ance errors. Dally/Dlp-injected Sdc mutant embryos
had more severe phenotypes, but ISNb guidance was
not selectively affected (data not shown). Overall, our
data suggest that Sdc is not redundant with Dally or
Dlp and that its absence is likely to be compensated
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gand that we detect by embryo staining is redundant
with Sdc. Like Sdc, this ligand is expressed both on
CNS axons and in lines in the periphery (Figure 2).
The genetic epistasis experiment of Figure 6 demon-
strates that Sdc acts in trans (as a ligand) to regulate
LAR function. However, these data allow us to reach
this conclusion only for SNa bifurcation, which is af-
fected by LAR overexpression but not by loss of LAR.
In its regulation of the decision of ISNb growth cones
to enter the muscle field, Sdc could also act as a ligand,
since it is expressed at the appropriate time on patches
of cells near the muscle field entry site that could be
contacted by LAR-expressing ISNb growth cones at
this choice point (Figure 5). Alternatively, Sdc could act
as a coreceptor at this choice point since it is ex-
pressed on the motor nerves together with LAR. Finally,
we do not know if the Sdc that interacts with LAR dur-
ing ISNb axon guidance is attached to the cell surface
or has been shed by proteolytic cleavage. If released
Sdc is the essential ligand, this could be expressed by
either muscles or neurons and transported to the choice
point.
Conclusions
Our results show that the cell-surface HSPG Sdc is an
in vivo ligand for LAR and indicate that it positively reg-
ulates LAR signaling during motor axon guidance.
Sdc’s GAG chains bind directly to LAR with high affinity,
and this binding requires basic sequences in the first
Ig domain of LAR. Further work will be required to de-
termine whether binding to Sdc directly stimulates
LAR’s phosphatase activity, relocalizes LAR within the
growth cone, or facilitates LAR signaling by another
mechanism.
Experimental Procedures
Genetics
SdcDf(2R)48, generated by imprecise excision of sdc10608, was pre-
viously described [20]. SdcKG06163, Sdc10608, sfl, sgl, ttv, pipe, trol,
dally11685, elav-Gal4, C155-Gal4, G14-Gal4, 24B-Gal4, and the defi-
ciency kit strains were obtained from the Bloomington stock center.
The Fkbp13 allele l(2)00734, Sara250, and ubi-Sara were obtained
from M. O’Connor. Larbypass was obtained from D. Van Vactor.
dally80 dlpA187 and UAS-Dlp were obtained from X. Lin. UAS-Lar-wt
and UAS-Lar-C1638S-C1929S were obtained from N. Krueger.
UAS-Dally lines were obtained from N. Perrimon’s and S. Selleck’s
groups. UAS-Sdc insertions on chromosomes II and III were ob-
tained from Tim Heslip. Lar13.2Sdc10608 and Lar5.5SdcDf48 were ob-
tained from Karl Johnson. Deficiency kit lines were balanced over
FM7c, P{GAL4-Kr.C}DC1,P{UAS-GFP.S65T}DC5,sn−, CyOarmGFP,
or TM3armGFP.
Immunohistochemistry
The desired mutant embryos were identified based on the absence
of staining with rabbit-anti-GFP (Molecular Probes; 1:1000), which
detects the presence of the GFP gene on the balancer chromo-
somes. mAb 1D4 [34] was used at 1:3 dilution to reveal motor axon
and CNS pathways, dissected, and photographed with a Magnafire
digital camera on a Zeiss Axioplan microscope using Nomarski op-
tics. Antibody staining using HRP immunohistochemistry was per-
formed as described [35].
Rabbit anti-Sdc was a gift from Tim Heslip and John Lincecum.
Anti-Dlp mAb supernatant was obtained from the Developmental
Studies Hybridoma Bank. Anti-Myc (Sigma; clone 9E10 [ascites
fluid]) was used at 1:250. Secondary antibodies conjugated to
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nither Alexa 488 or Alexa 568 (Molecular Probes) were used to visu-
lize antibody staining in the embryos.
inding Experiments
PTP-AP fusion proteins were incubated with 10 l (3.7 g heparin)
eparin-agarose beads (Sigma; preblocked with 1×PBS + 3% bo-
ine serum albumin [BSA] for 1 hr at room temperature) or with
c167 cells (Drosophila Genomics Resources Center, Indiana Uni-
ersity) or S2 cells (10 × 106 cells) for 3 hr at room temperature.
eparin-agarose beads or cells were washed extensively with
BAH (Hanks’ balanced salt solution: BSA [0.5 mg/ml], 0.1% [w/v]
aN3, 20 mM HEPES [pH 7.0]). Heparin-agarose beads were resus-
ended in 1× Hanks buffered saline (HBS: 150 mM NaCl, 20 mM
EPES [pH 7.0]), and cells were lysed with Triton-Tris lysis buffer
1% Triton X-100, 10 mM Tris [pH 8.0]). Endogenous alkaline phos-
hatase (AP) activity of the samples was quenched by a 10 min
ncubation at 65°C. AP activity was determined by adding SEAP
uffer (0.5 mM MgCl2, 1 M diethanolamine [pH 9.8]) containing 1
g/ml p-nitrophenyl phosphate (Sigma). Progress curves were re-
orded every 5 min for 1 hr at room temperature at 405 nm on
n EL312e biokinetics reader (Bio-Tek Instruments), and maximum
ates were determined by Delta Soft 3 software (version 2.243, Bio-
ek Instruments). Each data point represents the average of tripli-
ate reactions. Curves were generated using GraphPad Prism 4
oftware (GraphPad Software). Figure 3 data were normalized
gainst the amount of input AP fusion proteins, determined by im-
unoprecipitation of the AP fusion proteins with anti-PLAP and
rotein A/G beads followed by an AP assay, described above.
ransient Transfections
EK 293T cells were transiently transfected with pCMV-FLAG-Sdc-
CD (extracellular domain: aa 29–335) by use of FuGENE6 trans-
ection reagent (Roche). This construct has the endogenous Sdc
ignal sequence deleted and replaced with the gp67 signal se-
uence, and a C-terminal FLAG tag has been fused to the end of
he Sdc ECD at aa 335. 48 hr after transfection, conditioned media
ere collected and subjected to coimmunoprecipitation and other
inding assays.
oimmunoprecipitation Assays
onditioned media from HEK 293T cells transiently transfected
ith pCMV-FLAG-Sdc-ECD were incubated with Lar-AP fusion pro-
ein, anti-FLAG M2 mAb (Sigma), or anti-PLAP polyclonal antibody
nd Protein G Plus/Protein A-agarose beads (Oncogene Research
roducts). After 1 hr incubation at 4°C of conditioned media and
AR-AP, anti-FLAG mAb and Protein G Plus/Protein A-agarose
eads were added. After one more incubation at 4°C, the Protein
Plus/Protein A-agarose beads were extensively washed and sub-
ected to SDS-PAGE and Western blotting. The Western blot was
robed with anti-PLAP polyclonal antibody, goat-anti-rabbit-alka-
ine phosphatase secondary (Jackson Immunoresearch) and de-
ected with NBT/BCIP.
upplemental Data
upplemental Data include five figures, one table, and Supplemen-
al Experimental Procedures and can be found with this article
nline at http://www.current-biology.com/cgi/content/full/15/19/
701/DC1/.
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